# US 2017/0290770 A1 · Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0290770 A1
- Document ID: US20170290770A1
- Status: Published application
- Kind: A1
- Application number: 15/632,350
- Filed: 2017-06-25
- Published: 2017-10-12
- Earliest claimed: 2015-08-11
- Assignees: Issar Pharmaceutical
- Inventors: RAM ISANAKA; Jesse Jaynes
- Web page: https://patentgrep.com/patent/US20170290770A1

## CPC

- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/02: Inorganic compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antimicrobial peptides represent a relatively new discovery in the immune system pathway. Recent designs of synthetically engineered antimicrobial peptides have demonstrated increased potency and efficacy/tolerability, enhanced specificity, and reduced toxicity in comparison. One such peptide, XYLENTRA, has shown/demonstrated significant promise from significant in vitro studies against a large number of pathogens. Additionally, extensive animal studies have shown that the XYLENTRA is an antimicrobial peptide against a large number of pathogens. The XYLENTRA is also solute resistant. The test compound Xylentra® has shown/demonstrated significant antibacterial activity on test organisms Staphylococcus aureus MTCC 96 and Pseudomonas aeruginosa. MTCC741. A substantial decrease in the microbial population level was observed in animals treated with peptide using the protocol described in detail in the application

## Claims

### Claim 1

A wound treatment method yielding significant reduction in scarring caused from wounds said treatment in the form of a cream.

### Claim 2 (depends on 1)

The method of claim 1 for the treatment of wounds further comprising administering to a wound a therapeutically effective dose of a composition comprising an antimicrobial peptide said antimicrobial peptide comprising SEQ ID NO:1 (XYLANTRA).

### Claim 3 (depends on 1)

The method of claim 1 wherein said wound is a burn.

### Claim 4 (depends on 1)

The method of claim 1 wherein said wound is a diabetic wound.

### Claim 5 (depends on 2)

The method of claim 2 wherein said antimicrobial peptide exhibits antimicrobial activity on Staphylococcus aureus and Pseudomonas aeruginosa.
